Menu
LAUSANNE, Switzerland and Cambridge, UK – 17 November 2016: Sophia Genetics, the global leader in Data-Driven Medicine, and Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world-leader in the application of gene editing technologies, today announced they have entered into a new partnership to improve the quality of Next Generation Sequencing (NGS) based genetic testing in oncology patient samples.
Under the terms of the agreement, Horizon’s HDx™ Reference Standards will be combined with Sophia Genetics’ artificial intelligence, providing hospitals and laboratories with more accurate and high quality NGS testing services, assays and genomic data analysis.
In particular, current and future users of the Sophia DDM® analytical platform will be able to assess the quality of their NGS assays, reaching the highest levels of sensitivity and specificity. The use of HDx Reference Standards will help with performance monitoring as well as reproducibility and repeatability of NGS tests.
Jurgi Camblong, Chief Executive Officer and co-founder, Sophia Genetics, commented: “The quality of molecular profiling is a cornerstone of NGS testing and relies on a series of technical steps being performed correctly, from the collection of patient samples and DNA extraction, to creating and analysing genomic data. Sophia Genetics is helping hospitals and laboratories to make the most of their NGS testing and we are delighted to be combining Horizon’s Reference Standards with our artificial intelligence for Data-Driven Medicine, increasing the number of patients that will benefit from reliable NGS genomic testing results.”
Dr. Darrin M. Disley, Chief Executive Officer, Horizon Discovery Group, commented: “Our new partnership with Sophia Genetics demonstrates the increasingly important role well validated controls have in the provision of molecular assays, especially for complex technologies such as NGS as they become more widely adopted. We look forward to working closely with Sophia Genetics as our Reference Standards become an important component of their workflows.”
Financial terms for the partnership have not been disclosed.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
